RCC Monthly Rewind: September 2025 News & Insights

October 10, 2025 Jennifer Chen Health
News Context
At a glance
  • Here's a breakdown of the provided text, extracting the citations in ⁢a more readable format:
  • Note: The text appears to be HTML with some Astro.js specific tags.
Original source: onclive.com

Here’s a breakdown of the provided text, extracting the citations in ⁢a more readable format:

References:

  1. Dr. Chehrazi on the TiNivo-2 Study of Tivozanib wiht or without Nivolumab in mRCC. ‍OncLive.com. https://www.onclive.com/view/dr-chehrazi-raffle-on-the-tinivo-2-study-of-tivozanib-with-without-nivolumab-in-mrcc
  2. Dr. Chahoud on the safety of ALLO-316 in advanced ccRCC. OncLive.com. September 16, 2025. Accessed October 10,2025. https://www.onclive.com/view/dr-chahoud-on-the-safety-of-allo-316-in-advanced-ccrcc
  3. Dr. Haas on the rationale for evaluating adjuvant pembrolizumab in clear cell RCC. OncLive.com. ⁢(The full date⁤ details is missing from the provided snippet.)

Note: The text appears to be HTML with some Astro.js specific tags. I’ve extracted the relevant citation information and presented⁤ it in a standard reference format.

More on this